Table 1.
SJFLC patient cohort characteristics
| Patient ID | Sample type | Sample location | Age | Gender | Class I HLA type | Number of predicted fusion neoepitopes |
|---|---|---|---|---|---|---|
| FLC-SJ1 | expanded TILs | primary tumor |
21 | F | A∗31:01, A∗68:02, B∗35:02, B∗38:01, C∗04:01, C∗12:03 |
10 |
| PBMC | peripheral blood | |||||
| FLC-SJ2 | expanded TILs | primary tumor |
19 | F | A∗02:19, A∗23:01, B∗15:01, B∗14:01, C∗03:02, C∗05:01 |
5 |
| FLC-SJ3 | expanded TILs | ascites | 19 | F | A∗03:01, A∗23:01, B∗44:03, B∗55:01, C∗03:03, C∗04:01 |
6 |
| FLC-SJ4 | tumor | metastatic tumor | 15 | M | A∗01:01, A∗02:01, B∗37:01, B∗44:02, C∗05:01, C∗06:02 |
2 |
| FLC-SJ5 | tumor | primary tumor | 16 | F | A∗01:01, A∗32:01, B∗07:02, B∗44:02, C∗05:01, C∗07:02 |
5 |